Epidemiology: Benign Prostatic Hyperplasia - Expected to continue growing as the male population ages

NEW YORK, Aug. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Epidemiology: Benign Prostatic Hyperplasia – Expected to continue growing as the male population ages

http://www.reportlinker.com/p0591219/Epidemiology-Benign-Prostatic-Hyperplasia-–-Expected-to-continue-growing-as-the-male-population-ages.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Introduction

In 2010, Datamonitor estimates that there were 92.4 million prevalent cases of benign prostatic hyperplasia (BPH) in men over age 50 in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK); approximately 49% of these cases were symptomatic. The largest number of cases (28.4 million) was in the US.

Features and benefits

* Gain insight into market potential, including a robust 10-year epidemiology forecast of total and symptomatic prevalent cases of BPH.

* Understand the key epidemiologic risk factors associated with benign prostatic hyperplasia.

Highlights

Datamonitor expects to see an increase in the number of histologic benign prostatic hyperplasia (BPH) cases between 2010 and 2020 in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK). The number of total BPH cases is expected to increase from approximately 79.1 million cases in 2010 to 92.4 million cases in 2020.

Datamonitor expects to see an increase in the number of symptomatic benign prostatic hyperplasia (BPH) cases between 2010 and 2020 in the seven major markets. The number of symptomatic BPH cases is expected to increase from around 38.9 million cases in 2010 to 45.8 million cases in 2020.

The largest increase in the number of BPH cases is expected in the US for both total and symptomatic BPH. Between 2010 and 2020, the number of total prevalent cases of BPH will increase by 2.2% annually and the number of symptomatic BPH cases will increase by 2.4% annually.

Your key questions answered

* What are the most robust sources for benign prostatic hyperplasia prevalence data?

* How will the patient population change over the next decade in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK)?

* How do changes in population structure and risk factors affect the trend in prevalent benign prostatic hyperplasia cases?

Executive Summary

Epidemiology of benign prostatic hyperplasia

Benign prostatic hyperplasia in the seven major markets

Datamonitor's forecast of benign prostatic hyperplasia

OVERVIEW

Catalyst

Summary

DISEASE DEFINITION AND DIAGNOSTIC CRITERIA

Diagnosis definition and diagnosis of benign prostatic hyperplasia

Definition of benign prostatic hyperplasia

GLOBAL VARIATION AND HISTORICAL TRENDS

Global variation and historical trends in prevalence

The greatest variation in benign prostatic hyperplasia is in symptomatic prevalence, not total prevalence

Mortality trends

Mortality from benign prostatic hyperplasia has decreased significantly in the last 60 years

DRIVERS OF BENIGN PROSTATIC HYPERPLASIA EPIDEMIOLOGY

Age and genetics are the most significant risk factors, with controversy surrounding many other risk factors

Age is the most important risk factor for benign prostatic hyperplasia

There is a significant genetic link in the development of BPH

Some lifestyle factors may have an association with increased risk of benign prostatic hyperplasia

Some studied factors have shown conflicting results or no association with increased risk of benign prostatic hyperplasia

Some lifestyle factors have been found to protect against benign prostatic hyperplasia

Physical activity and moderate alcohol intake have been shown to reduce the risk of benign prostatic hyperplasia

Diseases with high prevalence rates in the elderly are often co-morbid with benign prostatic hyperplasia

Cardiovascular disease risk factors are highly co-morbid with benign prostate hyperplasia

Type 2 diabetes mellitus is co-morbid with benign prostatic hyperplasia, both common in the elderly

Sexual dysfunction is a common co-morbidity of benign prostatic hyperplasia

EPIDEMIOLOGIC FORECASTING OF BENIGN PROSTATIC HYPERPLASIA

Overview

Subpopulations

Age

Total prevalence of benign prostatic hyperplasia

Sources used

Methods

Symptomatic prevalence of benign prostatic hyperplasia

US

Japan

France

Germany

Italy

Spain

UK

EPIDEMIOLOGIC RESULTS

Total prevalent histologic cases and future trends

Total prevalent cases of histologic BPH by age group

Symptomatic prevalent cases and future trends

Symptomatic benign prostatic hyperplasia by age group

Age-standardized prevalence rates

DISCUSSION

Strengths and limits of Datamonitor's epidemiologic projections

Conclusions

BIBLIOGRAPHY

Journal papers

Websites

Datamonitor reports

APPENDIX

Module methodology

To order this report:

Pathology Industry: Epidemiology: Benign Prostatic Hyperplasia – Expected to continue growing as the male population ages

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker